Unknown

Dataset Information

0

Clinical benefits of adjuvant chemotherapy with carboplatin and gemcitabine in patients with non-small cell lung cancer: a single-center retrospective study.


ABSTRACT: PURPOSE:In cases of non-small cell lung cancer (NSCLC), surgery remains the best option for cure, but surgery is of benefit only when the disease is localized. Although adjuvant chemotherapy reportedly has a significant beneficial effect on survival, the benefit of a carboplatin (CBDCA) regimen is unclear. We therefore investigated the efficacy and tolerability of CBDCA (area under the curve 5) plus gemcitabine (GEM, 1000 mg/m2) as adjuvant chemotherapy. METHODS:A total of 82 pStage IB-IIIA NSCLC patients who had undergone complete resection and received adjuvant chemotherapy were analyzed retrospectively. Among them, 65 patients received CBDCA + GEM and 17 received CDDP + VNR. Propensity score analysis generated 17 matched pairs of both groups. RESULTS:Sixty-five patients received CBDCA + GEM. Their 5-year relapse-free survival (RFS) and overall survival were 47.8% (median, 52.5 months) and 76.9% (median, 90.1 months), respectively. Toxicities, which included neutropenia, nausea/anorexia, fatigue, and vasculitis, were significantly milder than with CDDP + VNR. There were no significant differences in RFS between CBDCA + GEM and CDDP + VNR (p = 0.079) after matching for age, performance status, and pStage. CONCLUSION:CBDCA + GEM was effective and well tolerated as adjuvant chemotherapy, with a manageable toxicity profile.

SUBMITTER: Takashima S 

PROVIDER: S-EPMC7545843 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Clinical benefits of adjuvant chemotherapy with carboplatin and gemcitabine in patients with non-small cell lung cancer: a single-center retrospective study.

Takashima Shinogu S   Imai Kazuhiro K   Atari Maiko M   Matsuo Tsubasa T   Nakayama Katsutoshi K   Sato Yusuke Y   Motoyama Satoru S   Shibata Hiroyuki H   Nomura Kyoko K   Minamiya Yoshihiro Y  

World journal of surgical oncology 20201008 1


<h4>Purpose</h4>In cases of non-small cell lung cancer (NSCLC), surgery remains the best option for cure, but surgery is of benefit only when the disease is localized. Although adjuvant chemotherapy reportedly has a significant beneficial effect on survival, the benefit of a carboplatin (CBDCA) regimen is unclear. We therefore investigated the efficacy and tolerability of CBDCA (area under the curve 5) plus gemcitabine (GEM, 1000 mg/m<sup>2</sup>) as adjuvant chemotherapy.<h4>Methods</h4>A total  ...[more]

Similar Datasets

| S-EPMC4391757 | biostudies-literature
| S-EPMC9402945 | biostudies-literature
| S-EPMC3815738 | biostudies-literature
| S-EPMC3619002 | biostudies-literature
| S-EPMC3691357 | biostudies-literature
| S-EPMC7475383 | biostudies-literature
| S-EPMC9058885 | biostudies-literature
| S-EPMC6441112 | biostudies-literature
| S-EPMC8046076 | biostudies-literature
| S-EPMC4384209 | biostudies-literature